Liquidia (LQDA) Revenue Growth (3y) (2023 - 2026)
Liquidia (LQDA) Revenue Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 2.94% |
| 10 | Liquidia | 7.61 Bn | 7.39 Bn | 121.79 Mn | 209.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.24% |
| Dec 31, 2025 | 157.97% |
| Sep 30, 2025 | 157.98% |
| Jun 30, 2025 | 31.14% |
| Mar 31, 2025 | -3.69% |
| Dec 31, 2024 | -3.19% |
| Sep 30, 2024 | 11.85% |
| Jun 30, 2024 | 2.72% |
| Mar 31, 2024 | -1.23% |
| Dec 31, 2023 | 82.98% |